Company / Operating Cash Flow
Gilead Sciences Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$10.0B
FY2025
5-year range
$8.2B / $11.4B
FY2021-FY2025
Trend
-7.5%
vs FY2024
Sector context
#7 of 216
Health Care
What the data says
Among 216 Health Care companies, Gilead Sciences is in the top 3% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $8.2B in FY2022 to $21.3B in FY2017.
Based on SEC 10-K filings.
$10.0B in FY2025 with a 5-year CAGR of +4.2%. Top quartile in the Health Care sector.
Declined from $11.4B to $10.0B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +7.0%
- 5-Year CAGR
- +4.2%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 216This company $10.0B Sector average $658.7M
▼
+1421.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.2%, indicating consistent growth.
- In FY2025, operating cash flow decreased 7.5% year-over-year.
- Ranks #7 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.0B | -7.5% |
| FY2024 | $10.8B | -4.9% |
| FY2023 | $11.4B | +39.4% |
| FY2022 | $8.2B | -10.7% |
| FY2021 | $9.1B | +11.9% |
| FY2020 | $8.2B | -31.3% |
| FY2019 | $11.9B | -30.2% |
| FY2018 | $17.0B | -19.8% |
| FY2017 | $21.3B | +65.8% |
| FY2016 | $12.8B | -39.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026